Scientists discover promising target to block Staphylococcus infection

National Institutes of Health (NIH) scientists have identified a promising lead for developing a new type of drug to treat infection caused by Staphylococcus aureus, a bacterium that frequently resists traditional antibiotics.

The researchers discovered a system used by S. aureus to transport toxins that are thought to contribute to severe . These toxins—called phenol-soluble modulins (PSMs)—have gained much attention in recent years, but their multitude and diversity have hindered efforts to target them for drug development.

Expanding on work that first described S. aureus PSMs in 2007, scientists at the NIH's National Institute of Allergy and Infectious Diseases found that the transport system, which they call Pmt, is common to all S. aureus PSMs and critical for bacterial proliferation and disease development in a . Their experiments suggest that a drug interfering with Pmt's function could not only prevent production of the PSM toxins, but also directly lead to bacterial death.

Although their study focused on S. aureus, the scientists suspect that Pmt performs the same role in other , such as S. epidermidis, the leading cause of hospital-associated infections involving indwelling medical devices such as catheters, pacemakers and prosthetics. They plan to continue their studies to improve the understanding of how PSMs function and to learn how to interfere with the Pmt transport system to block disease.

More information: S Chatterjee et al. Essential Staphylococcus aureus toxin export system. Nature Medicine, DOI: 10.1038/nm3047 (2013).

R Wang et al. Identification of novel cytolytic peptides as key virulence determinants of community-associated MRSA. Nature Medicine, DOI: 10.1038/nm1656 (2007).

Related Stories

Evolution of virulence regulation in Staphylococcus aureus

Oct 09, 2008

Scientists have gained insight into the complex mechanisms that control bacterial pathogenesis and, as a result, have developed new theories about how independent mechanisms may have become intertwined during evolution. The ...

Recommended for you

Africa's uneven health care becomes easy prey for Ebola

38 minutes ago

The disparity in African countries' ability to fight Ebola has left the continent fighting an uneven struggle against a disease that doesn't respect borders—yet relatively simple measures could help, experts say.

Ebola case stokes concerns for Liberians in Texas

1 hour ago

The first case of Ebola diagnosed in the U.S. has been confirmed in a man who recently traveled from Liberia to Dallas, sending chills through the area's West African community whose leaders urged caution ...

Is Australia prepared for Ebola?

4 hours ago

Australia needs to be proactive about potential disease outbreaks like Ebola and establish a national centre for disease control.

Dallas hospital confirms first Ebola case in US

10 hours ago

A patient at a Dallas hospital has tested positive for Ebola, the first case of the disease to be diagnosed in the United States, federal health officials announced Tuesday.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

sedona_cole_5
not rated yet Mar 11, 2013
Great to see such innovation on the war on staph and MRSA. Fortunately, yet all to little known, Microbiologist, Michelle Moore has successfully developed a very effective treatment for staph after having her own resistant case! Talk about being proactive and using her education. I only wish her work was better known, to help spare countless others of their pain, suffering, and possibly worse. Her information is at staph-infection-resources.com. Great information. Thank-you for sharing it.